Loading...
XNAS
GYRE
Market cap626mUSD
Jul 09, Last price  
6.86USD
1D
0.00%
1Q
-7.17%
Jan 2017
-95.31%
IPO
-99.95%
Name

Catalyst Biosciences Inc

Chart & Performance

D1W1MN
XNAS:GYRE chart
P/E
124.71
P/S
5.38
EPS
0.06
Div Yield, %
—
Shrs. gr., 5y
40.01%
Rev. gr., 5y
40.96%
Revenues
117m
+10.24%
27,537,56411,575,93120,085,00025,062,00085,713,00097,637,00057,860,0003,629,000275,0001,750,000399,0001,018,0006,000020,948,0007,338,000102,290,000113,450,000105,757,000116,588,000
Net income
5m
-58.40%
2,096,529-28,072,887-25,661,000-39,404,00010,899,000-8,529,000-6,998,000-46,705,000-32,623,000-14,762,000-16,945,000-21,561,000-30,055,000-55,178,000-55,542,000-87,933,0002,302,000-92,933,00012,085,0005,027,000
CFO
1m
P
-9,892,27724,838,076-28,261,000-24,271,000138,298,000-83,718,000-64,239,000-40,612,000-34,483,000-19,118,000-18,472,000-19,940,000-28,553,000-43,613,000-55,048,000-83,755,00010,677,00025,892,000-3,641,0001,010,000
Dividend
Jan 13, 20230.24 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
URL
https://www.catalystbiosciences.com/
IPO date
Apr 12, 2006
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT